Literature DB >> 29195045

Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor.

Khuraijam Dhanachandra Singh1, Hamiyet Unal1, Russell Desnoyer1, Sadashiva S Karnik1.   

Abstract

Crystal structures of the human angiotensin II type 1 receptor (AT1R) complex with the antihypertensive agent ZD7155 (PDB id: 4YAY ) and the blood pressure medication Benicar (PDB id: 4ZUD ) showed that binding poses of both antagonists are similar. This finding implies that clinically used angiotensin receptor blocking (ARB) drugs may interact in a similar fashion. However, clinically observed differences in pharmacological and therapeutic efficacies of ARBs lead to the question of whether the dynamic interactions of AT1R with ARBs vary. To address this, we performed induced-fit docking (IFD) of eight clinically used ARBs to AT1R followed by 200 ns molecular dynamic (MD) simulation. The experimental Ki values for ARBs correlated remarkably well with calculated free energy with R2 = 0.95 and 0.70 for AT1R-ARB models generated respectively by IFD and MD simulation. The eight ARB-AT1R complexes share a common set of binding residues. In addition, MD simulation results validated by mutagenesis data discovered distinctive spatiotemporal interactions that display unique bonding between an individual ARB and AT1R. These findings provide a reasonably broader picture reconciling the structure-based observations with clinical studies reporting efficacy variations for ARBs. The unique differences unraveled for ARBs in this study will be useful for structure-based design of the next generation of more potent and selective ARBs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29195045      PMCID: PMC6058968          DOI: 10.1021/acs.jcim.7b00424

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  44 in total

1.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

2.  A Monte Carlo simulation study of methane clathrate hydrates confined in slit-shaped pores.

Authors:  Somendra Nath Chakraborty; Lev D Gelb
Journal:  J Phys Chem B       Date:  2012-02-09       Impact factor: 2.991

3.  Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor.

Authors:  Hamiyet Unal; Rajaganapathi Jagannathan; Manjunatha B Bhat; Sadashiva S Karnik
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

4.  Hydrostatic pressure induces hydrocarbon chain interdigitation in single-component phospholipid bilayers.

Authors:  L F Braganza; D L Worcester
Journal:  Biochemistry       Date:  1986-05-06       Impact factor: 3.162

5.  Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.

Authors:  Y Kohara; K Kubo; E Imamiya; T Wada; Y Inada; T Naka
Journal:  J Med Chem       Date:  1996-12-20       Impact factor: 7.446

Review 6.  Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.

Authors:  D P Brooks; E H Ohlstein; R R Ruffolo
Journal:  Am Heart J       Date:  1999-09       Impact factor: 4.749

7.  Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor.

Authors:  S Miura; Y H Feng; A Husain; S S Karnik
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

Review 8.  Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials.

Authors:  Magnus Baumhäkel; Michael Böhm
Journal:  Vasc Health Risk Manag       Date:  2011-06-23

Review 9.  Differential pharmacology and benefit/risk of azilsartan compared to other sartans.

Authors:  Theodore W Kurtz; Takashi Kajiya
Journal:  Vasc Health Risk Manag       Date:  2012-02-28

10.  Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers.

Authors:  Shin-Ichiro Miura; Naoki Nakao; Hiroyuki Hanzawa; Yoshino Matsuo; Keijiro Saku; Sadashiva S Karnik
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

View more
  6 in total

1.  Angiotensin Type 1 Receptor Blockers in Heart Failure.

Authors:  Khuraijam Dhanachandra Singh; Sadashiva S Karnik
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

Review 2.  Structural perspectives on the mechanism of signal activation, ligand selectivity and allosteric modulation in angiotensin receptors: IUPHAR Review 34.

Authors:  Khuraijam Dhanachandra Singh; Sadashiva S Karnik
Journal:  Br J Pharmacol       Date:  2022-04-23       Impact factor: 9.473

3.  Mechanism of Hormone Peptide Activation of a GPCR: Angiotensin II Activated State of AT1R Initiated by van der Waals Attraction.

Authors:  Khuraijam Dhanachandra Singh; Hamiyet Unal; Russell Desnoyer; Sadashiva S Karnik
Journal:  J Chem Inf Model       Date:  2019-01-16       Impact factor: 4.956

4.  Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers.

Authors:  Khuraijam Dhanachandra Singh; Zaira P Jara; Terri Harford; Prasenjit Prasad Saha; Triveni R Pardhi; Russell Desnoyer; Sadashiva S Karnik
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-17       Impact factor: 11.205

5.  Computational Insights and In Vitro Validation of Antibacterial Potential of Shikimate Pathway-Derived Phenolic Acids as NorA Efflux Pump Inhibitors.

Authors:  Karishma Singh; Roger M Coopoosamy; Njabulo J Gumede; Saheed Sabiu
Journal:  Molecules       Date:  2022-04-18       Impact factor: 4.927

6.  Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model.

Authors:  Wael A Alanazi; Hussain N Alhamami; Metab Alharbi; Khalid Alhazzani; Abdulrahman S Alanazi; Sary Alsanea; Nemat Ali; Abdullah F Alasmari; Ahmed Z Alanazi; Moureq R Alotaibi; Mohammed Alswayyed
Journal:  Saudi Pharm J       Date:  2022-06-22       Impact factor: 4.562

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.